Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy  

作　　者：Wen-Xin Luo Lan Yang Wei-Min Li 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China.

出　　处：《Chinese Medical Journal》2021年第7期780-782,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China to Wei-Min Li(No.81871890)。

摘　　要：Worldwide,lung cancer is the most common malignancy and the leading cause of cancer-related death.After the era of chemotherapy,radiotherapy,and molecular-targeted therapy,the treatment of advanced lung cancer has entered a new era of immunotherapy,represented by immune checkpoint inhibitors(ICIs),including programmed cell death protein-1/programmed cell death protein ligand-1(PD-1/PD-L1)inhibitors and cytotoxic T-lymphocyte-associated antigen-4(CTLA-4)inhibitors.[1]However,patients treated with ICIs may experience unexpected systemic toxicities,some fatal.Thus,managing immunotherapy-related toxicity has become increasingly significant in patients with lung cancer.Here,we review the latest developments on the clinical features and management of immunotherapy-related toxicity in patients with lung cancer in order to promote the standardization of immunotherapy for lung cancer.

关 键 词：LUNG clinical cancer 

分 类 号：R734.2[医药卫生—肿瘤]